Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Durcabtagene autoleucel, a BCMA-directed CAR T manufactured w/ rapid platform to preserve T cell stemness shows ORR 98%, sCR 55%, 80% of pts (35/44) achieved MRD-negativity, no unexpected safety findings, delayed neurotox.”
Title: Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
Authors: Adam S. Sperling, Benjamin A. Derman, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Nina Orwitz, David S. Quinn, David Pearson, Dexiu Bu, Pedro Milanez-Almeida, Jennifer Mataraza, Omar Nadeem, Jessica Liegel, Anita D’Souza, Allison Charles, Marc Credi, Jerome Ritz, Andrzej J. Jakubowiak, Serena De Vita, Nikhil C. Munshi
You can read the Full Article in Science Translational Medicine.
You can find other articles featuring Robert Orlowski on OncoDaily.
